Gedea Biotech AB i Lund 559000-7026 - Merinfo.se

Hur man tjänar pengar: 69 originella sätt: Bioteknikföretag från

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Gedea Biotech. Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections, a major problem that affects about 75% of all women at some point in life. Gedea Biotech´s substance, GA101, acts by lowering pH as well as providing a physical barrier protection and inhibiting biofilm formation. Placera Biotech-index i USA, Nasdaq Biotechnology Index, har utvecklats nästan dubbelt så bra som det bredare indexet S&P 500 under de senaste tio åren.

Gedea biotech aktie

Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech NEFERTITI clinical study NEFERTITI aims to recruit 150 adult women aged 18 or over with bacterial vaginosis diagnosed by Amsel’s* criteria and is due to start in late 2020. pHyph has been shown to have an excellent medical effect.A total of 82% of the subjects were clinically cured of bacterial vaginosis by day seven. pHyph is being developed to both cure bacterial vaginosis and prevent recurrence. Gedea Biotech, a biotech company started by a multidisciplinary team from Lund University, that develops an antibiotic-free treatment for vaginal infections named pHyph. pHyph can be used to treat vaginal thrush and bacterial vaginosis.

Active Biotech offentliggör de slutliga villkoren för - Börskollen

Gedea Biotech is the only Swedish company on Labiotech's annual list "The 21 European Biotech Companies to Watch in 2021". Labiotech has run articles about Gedea several times, focusing on our ambition to develop a treatment that not only treats but also prevents recurrence of bacterial vaginosis and provides a true alternative to antibiotics.

Recipharm säljer aktier - Life Science Sweden

We aim to develop effective treatments that are sustainable for both patients and the wider world.

Gedea Biotech was started by a multidisciplinary team from Lund University. The broad competence of our employees is the basis for our success. Today, we are approaching clinical trials and a product launch. Everything points towards pHyph reaching its potential in achieving an attractive position in a market with high medical needs. Gedea Biotech is developing a vaginal pill that could tackle bacterial vaginosis without the drawbacks of antibiotics.
Palma and nardozza

The grant will fund completion of the clinical trial program and preparation work for market introduction of the company’s antibiotic-free treatment for vaginal infections. Jag är också styrelseledamot i Gedea Biotech AB samt Nordic Rebalance a / s och äger MS Persson Consulting AB där jag hjälper företag med strategiska Gedea Biotech AB. Haeger & Carlsson.

Everything points towards pHyph reaching its potential in achieving an attractive position in a market with high medical needs. Gedea Biotech has announced that all patients have been recruited for the multi-center study evaluating the clinical performance of an antibiotic-free treatment for vaginal infections. This pilot study marks the start of a clinical development program of a treatment with dual effect, targeting both vaginal bacterial and fungal infections. Gedea Biotech reports that all 24 patients have been treated with its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis in a proof of concept clinical study.
Kollega slutar rim

skyltbelysning slapvagn
hastighet husbil tyskland
bilbolaget kiruna blocket
hennings kläder instagram
fyrbodal kommunalförbund
hotmail.com logg in

Hur man tjänar pengar: 69 originella sätt: Bioteknikföretag från

Labiotech has run articles about Gedea several times, focusing on our ambition to develop a treatment that not only treats but also prevents recurrence of bacterial vaginosis and provides a true alternative to antibiotics. Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech NEFERTITI clinical study NEFERTITI aims to recruit 150 adult women aged 18 or over with bacterial vaginosis diagnosed by Amsel’s* criteria and is due to start in late 2020. pHyph has been shown to have an excellent medical effect.A total of 82% of the subjects were clinically cured of bacterial vaginosis by day seven.